BrdU Monoclonal Antibody for IF, IHC, ELISA
Cat no : 66241-1-Ig
5-bromo-2-deoxyuridine, BrDu, BrdUrd, Bromodeoxyuridine, BUdR
|Positive IHC detected in||mouse spleen tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Immunohistochemistry (IHC)||IHC : 1:200-1:1000|
|Immunofluorescence (IF)||IF : 1:150-1:600|
|Sample-dependent, check data in validation data gallery|
66241-1-Ig targets BrdU in IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
Bromodeoxyuridine (5-bromo-2'-deoxyuridine, BrdU, BUdR, BrdUrd) is a synthetic nucleoside that is an analog of thymidine. It can be incorporated into the newly synthesized DNA of replicating cells (during the S phase of the cell cycle), substituting for thymidine during DNA replication. As such, BrdU is used for birth dating and monitoring cell proliferation. BrdU is a toxic and mutagenic substance. It triggers cell death, the formation of teratomas, alters DNA stability, lengthens the cell cycle, and has mitogenic, transcriptional and translational effects on cells that incorporate it. This antibody does not cross react with Thymidine.
Clin Sci (Lond)
Activation of G protein-coupled estrogen receptor protects intestine from ischemia/reperfusion injury in mice by protecting the crypt cell proliferation.
Int J Ophthalmol
Oxidative stress affects retinal pigment epithelial cell survival through epidermal growth factor receptor/AKT signaling pathway.
Biochem Biophys Res Commun
MicroRNA-99a inhibits insulin-induced proliferation, migration, dedifferentiation, and rapamycin resistance of vascular smooth muscle cells by inhibiting insulin-like growth factor-1 receptor and mammalian target of rapamycin.
MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice.
Correction: Auranofin Inhibits Retinal Pigment Epithelium Cell Survival through Reactive Oxygen Species-Dependent Epidermal Growth Factor Receptor/ Mitogen-Activated Protein Kinase Signaling Pathway.
J Cell Biochem
microRNA-31 inhibition partially ameliorates the deficiency of bone marrow stromal cells from cleidocranial dysplasia.